These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24803917)

  • 21. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
    Nogami A; Harada T; Sekiguchi Y; Otani R; Yoshida Y; Yoshida K; Nakano Y; Nuruki N; Nakahara S; Goya M; Origasa H; Kihara Y; Hirao K; Aonuma K;
    JAMA Netw Open; 2019 Apr; 2(4):e191994. PubMed ID: 31002317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation.
    Wang SV; Huybrechts KF; Fischer MA; Franklin JM; Glynn RJ; Schneeweiss S; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2018 Apr; 27(4):383-390. PubMed ID: 29383858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
    Singh SM; Micieli A; Wijeysundera HC
    Circulation; 2013 Jun; 127(24):2414-23. PubMed ID: 23697908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil.
    Monteiro JMC; San-Martin DL; Silva BCG; Souza IFB; Oliveira Filho J; Jesus P
    Arq Neuropsiquiatr; 2019 Feb; 77(2):80-83. PubMed ID: 30810590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report series of left atrial thrombus formation in patients on dabigatran therapy.
    Sharma S; Singh S; Sandhu R; Monterroso M; Bhambi N; Sharma R
    Am J Ther; 2014; 21(3):e71-4. PubMed ID: 23803980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR; Armstrong EP; Nolan PE; Malone DC
    Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
    Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
    BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    Blommel ML; Blommel AL
    Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
    Mumoli N; Mastroiacovo D; Tamborini-Permunian E; Vitale J; Giorgi-Pierfranceschi M; Cei M; Dentali F
    J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):467-477. PubMed ID: 28509761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Case of a Thrombotic Storm (Arterial and Venous) in Nephrotic Syndrome.
    Wireko F; Nanduri S; Lyonga Ngonge A; Ikwu I; Poddar V
    Cureus; 2022 Jul; 14(7):e27505. PubMed ID: 36060380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dabigatran for the prevention and treatment of thromboembolic disorders.
    Enriquez A; Baranchuk A; Redfearn D; Simpson C; Abdollah H; Michael K
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):529-40. PubMed ID: 25843430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
    Maddox W; Kay GN; Yamada T; Osorio J; Doppalapudi H; Plumb VJ; Gunter A; McElderry HT
    J Cardiovasc Electrophysiol; 2013 Aug; 24(8):861-5. PubMed ID: 23577951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolving role of dabigatran etexilate in clinical practice.
    Hellenbart E; Drambarean B; Lee J; Nutescu EA
    Expert Opin Pharmacother; 2015; 16(13):2053-72. PubMed ID: 26245513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome.
    Sexton DJ; de Freitas DG; Little MA; McHugh T; Magee C; Conlon PJ; O'Seaghdha CM
    Kidney Int Rep; 2018 Jul; 3(4):784-793. PubMed ID: 29989039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.